Big Pharma’s Big Debate Win
Sometimes silence is golden. The first Presidential debate had lots of noise – but no discussion of health care, much less drug pricing. And, as an added bonus, both candidates agreed that tax repatriation is a good idea.
You may also be interested in...
The Presidential debates are over, and the biopharmaceutical industry has to be counted among the winners, simply because there was no substantive discussion of high drug prices as an issue. That may not mean much come 2017 – but at least the industry’s reputation hasn’t been further damaged during the highest profile phase of the national campaign.
Second Presidential debate included the first direct discussion of health care issues by the candidates, and the first reference to prescription drug costs. The passing reference was, to put it mildly, overshadowed by other topics.
The presidential campaign is about to begin in earnest, and for biopharma companies, the biggest question is what the outcome will mean for the pricing climate in the US. It isn’t an easy question to answer.